Abstract
Mantle cell lymphoma (MCL) is a unique, recently recognized entity with a variable clinical course [1]. Its historical grouping as an indolent lymphoma belies its common behavior, which is generally aggressive and incurable, with a median survival of about 5 years with modern therapy [2]. In an effort to improve outcomes in MCL, intensified therapies, including the rituximab plus HyperCVAD regimen [3] and incorporation of hematopoetic progenitor cell transplantation (HPCT) [4-6], have been used. However, although capable of inducing remissions in most patients, there is little proof that intensive first-line therapy prolongs overall survival (OS), and a continual relapse pattern is commonly observed [4,7-10].
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Dexamethasone / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Follow-Up Studies
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Kaplan-Meier Estimate
-
Lymphoma, Mantle-Cell / classification*
-
Lymphoma, Mantle-Cell / drug therapy
-
Lymphoma, Mantle-Cell / mortality
-
Lymphoma, Mantle-Cell / surgery
-
Male
-
Middle Aged
-
Prognosis
-
Retrospective Studies
-
Rituximab
-
Severity of Illness Index*
-
Transplantation, Autologous
-
Transplantation, Homologous
-
Vincristine / administration & dosage
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Rituximab
-
Vincristine
-
Dexamethasone
-
Doxorubicin
-
Cyclophosphamide